Please upgrade your browser.
Bristol-Myers Squibb Company BMY announced that the FDA accepted its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo for the indication first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb). The FDA set an action date of Feb 20, 2019.
Ipsen, a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS).
Emergency department visits, including those that resulted in hospital admissions, grew an average 4 percent every year from 2010 to 2016.
KEYNOTE-427 is a single-arm, open-label, non-randomized, multi-cohort, Phase 2 study evaluating the safety and efficacy of KEYTRUDA as monotherapy in patients with advanced RCC who have not received prior systemic therapy.
To evaluate trends in the use of partial nephrectomy in the United States, researchers collected information about more than 48,000 patients with non-metastatic kidney cancer treated between 1998 and 2007.
The Kidney Cancer Association has announced the winners of its annual Young Investigator Award (YIA). The award provides funding to promising doctors to pursue careers in kidney cancer research.
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.
A single damaged cell may be all it takes to trigger aggressive and terminal kidney cancer almost a lifetime after the first step towards the disease is taken.
Lead study author Aaron Mitchell said they also found prescriptions increased as the amount of money physicians received went up. Payments for research, by contrast, were not associated with statistically significant differences in prescribing.
A new technology has shown promise in treating several types of tumors in mice that do not respond to cancer immunotherapy medications called checkpoint inhibitors.
|NeonCRM by Neon One|